Last €64.15 EUR
Change Today +0.50 / 0.79%
Volume 568.0
As of 3:40 PM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

eli lilly & co (LLY) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/23/15 - €65.00
52 Week Low
04/8/14 - €40.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ELI LILLY & CO (LLY)

eli lilly & co (LLY) Details

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency. It also provides neuroscience products for the treatment of major depressive disorders, diabetic peripheral neuropathic pain, anxiety disorders, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorders; depressive, obsessive-compulsive, bulimia nervosa, and panic disorders; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains. In addition, the company offers products for the treatment of non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products for the treatment of erectile dysfunction and benign prostatic hyperplasia, thrombotic cardiovascular events, and cardiac ischemic complications. Further, it provides animal health products, such as cattle feed additives; protein supplements for cows; leanness and performance enhancers for swine, cattle, and poultry; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; anticoccidial agents for poultry; and chewable tablets that kill fleas and prevent flea infestations, heartworm diseases, roundworm diseases, hookworm diseases, and whipworm diseases, as well as controls intestinal parasite infections in dogs. Additionally, the company offers products to treat chronic manifestations of atopic dermatitis and congestive heart failure in dogs; chronic allergic dermatitis and kidney diseases in cats. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

39,135 Employees
Last Reported Date: 02/19/15
Founded in 1876

eli lilly & co (LLY) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.5M
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $1.0M
Executive Vice President of Science & Technol...
Total Annual Compensation: $1.0M
Senior Vice President and President of Lilly ...
Total Annual Compensation: $680.7K
Senior Vice President and General Counsel
Total Annual Compensation: $765.0K
Compensation as of Fiscal Year 2013.

eli lilly & co (LLY) Key Developments

Denovo Biopharma, LLC Licenses Late-Stage Neuroscience Drug from Eli Lilly and Company for Development as Personalized Medicine

Denovo Biopharma, LLC announced that it has exclusively licensed Pomaglumetad Methionil (mGlu2/3 receptor agonist), a late-stage neuroscience drug, from Eli Lilly and Company. Denovo gains all rights to develop, manufacture and commercialize pomaglumetad globally, including transfer of all intellectual property and other rights, data, and information. Lilly has an option to re-acquire pomaglumetad upon a successful clinical trial, for predetermined undisclosed financial terms. Pomaglumetad was primarily developed and tested in schizophrenia, including in Phase 2 and Phase 3 clinical trials. Predefined sub-population analysis and post-hoc analysis across multiple studies identified a meaningful subset of patients who showed significantly improved outcomes, although pomaglumetad did not meet the primary endpoint in the intent-to-treat population in Phase 3 studies. Denovo will use its proprietary platform to identify genetic biomarkers as a companion diagnostic to screen for appropriate patient subsets in future clinical trials and eventual commercialization.

Eli Lilly and Company Announces Issuance and Sale of $600,000,000 Aggregate Principal Amount of its 1.250% Notes Due 2018

On February 24, 2015, Eli Lilly and Company entered into an Underwriting Agreement between the Company and Deutsche Bank Securities Inc., Goldman, Sachs & Co. and Morgan Stanley & Co. LLC, as representatives of the several underwriters named therein, for the issuance and sale by the Company of $600,000,000 aggregate principal amount of its 1.250% Notes due 2018, $800,000,000 aggregate principal amount of its 2.750% Notes due 2025 and $800,000,000 aggregate principal amount of its 3.700% Notes due 2045 (the 2045 Notes, and together with the 2018 Notes and the 2025 Notes, the Notes). The Notes are to be issued pursuant to an Indenture, dated February 1, 1991, between the Company and Deutsche Bank Trust Company Americas, as successor to Citibank, N.A., as trustee, and an officer's certificate setting forth the terms of the Notes. The offering of the Notes was registered on a Registration Statement on Form S-3 (File No. 333-186979). The 2018 Notes accrue interest at a rate of 1.250% per annum, payable semiannually, and mature on March 1, 2018. The 2025 Notes accrue interest at a rate of 2.750% per annum, payable semiannually, and mature on June 1, 2025. The 2045 Notes accrue interest at a rate of 3.700% per annum, payable semiannually, and mature on March 1, 2045. At the closing of the offering of Notes, which is expected to occur on March 5, 2015, the company will realize, after deduction of the underwriter's discount and before deduction of offering expenses, net proceeds of approximately $2,181,948,000.

Cerecor Purchases Rights from Eli Lilly to Develop LY2456302

Cerecor reported that it has acquired exclusive, worldwide rights from Eli Lilly and Company to develop and commercialize LY2456302, a Phase 2-ready, potent and selective kappa opioid receptor antagonist. KORs are believed to play a key role in modulating stress, mood and addictive disorders. Research also suggests that selective KOR antagonists can block both the physical and emotional symptoms of nicotine withdrawal. CERC-501 was discovered and developed by Lilly for the treatment of co-occurring disorders, defined as a patient having one or more disorders relating to substance abuse combined with one or more mental health disorders. In Phase 1 clinical studies, CERC-501 was well tolerated, penetrated the blood-brain barrier and demonstrated target engagement, as shown through PET (positron emission tomography) imaging.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LLY:GR €64.15 EUR +0.50

LLY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $47.44 USD +0.43
AbbVie Inc $56.86 USD -3.41
Actavis plc $295.70 USD -0.44
AstraZeneca PLC 4,487 GBp +63.00
Novo Nordisk A/S kr318.00 DKK +2.40
View Industry Companies

Industry Analysis


Industry Average

Valuation LLY Industry Range
Price/Earnings 31.7x
Price/Sales 3.9x
Price/Book 4.9x
Price/Cash Flow 32.8x
TEV/Sales 3.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ELI LILLY & CO, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at